Leaderspeak Kurt Stoeckli
Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals, talks to P.B. Jayakumar about the latest trends in drug research globally.
- Feb 4, 2017,
- Updated Feb 7, 2017 3:10 PM IST
New drug research is not gaining a big ecosystem in India due to apprehensions about patent protection system and quality concerns. The regulatory requirements are different in the generic space than in innovative drug development. A company with a generics business working towards innovative medicines must make significant investments in protected industry assets that fulfil the highest standards. Licensing has been an integral part of our business strategy. But new drug research requires robust business development in a highly collaborative environment. We should have 'partners in development' who shoulder the responsibility of taking a drug from the clinic to the market. ~
New drug research is not gaining a big ecosystem in India due to apprehensions about patent protection system and quality concerns. The regulatory requirements are different in the generic space than in innovative drug development. A company with a generics business working towards innovative medicines must make significant investments in protected industry assets that fulfil the highest standards. Licensing has been an integral part of our business strategy. But new drug research requires robust business development in a highly collaborative environment. We should have 'partners in development' who shoulder the responsibility of taking a drug from the clinic to the market. ~